Literature DB >> 31687101

Cardiovascular Risk of Proton Pump Inhibitors.

Hannah Ariel1, John P Cooke1.   

Abstract

Proton pump inhibitors (PPIs) are effective agents for the treatment of gastroesophageal reflux (GERD). However, these drugs have not been approved for long-term use. Now sold over the counter, these agents are being used chronically for GERD without medical supervision. The long-term use of PPIs may have significant adverse effects, in part mediated by their effect of accelerating vascular aging. Physicians should assist patients in tapering off their use of PPIs and replacing them with lifestyle modifications and/or other agents that have better long-term safety profiles.
© 2019 Houston Methodist Hospital Houston, Texas.

Entities:  

Keywords:  GERD; H2 antagonists; gastroesophageal reflux disease; proton pump inhibitor

Mesh:

Substances:

Year:  2019        PMID: 31687101      PMCID: PMC6822659          DOI: 10.14797/mdcj-15-3-214

Source DB:  PubMed          Journal:  Methodist Debakey Cardiovasc J        ISSN: 1947-6108


  30 in total

1.  Clopidogrel with or without omeprazole in coronary artery disease.

Authors:  Deepak L Bhatt; Byron L Cryer; Charles F Contant; Marc Cohen; Angel Lanas; Thomas J Schnitzer; Thomas L Shook; Pablo Lapuerta; Mark A Goldsmith; Loren Laine; Benjamin M Scirica; Sabina A Murphy; Christopher P Cannon
Journal:  N Engl J Med       Date:  2010-10-06       Impact factor: 91.245

Review 2.  A comprehensive review of the loop diuretics: should furosemide be first line?

Authors:  Kurt A Wargo; William M Banta
Journal:  Ann Pharmacother       Date:  2009-10-20       Impact factor: 3.154

3.  Proton pump inhibitors and hypomagnesemia: a rare but serious complication.

Authors:  Mark A Perazella
Journal:  Kidney Int       Date:  2013-04       Impact factor: 10.612

4.  No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis.

Authors:  Chun Shing Kwok; Vinodh Jeevanantham; Buddhadeb Dawn; Yoon Kong Loke
Journal:  Int J Cardiol       Date:  2012-03-30       Impact factor: 4.164

Review 5.  Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint.

Authors:  Helge L Waldum; Gunnar Qvigstad; Reidar Fossmark; Per M Kleveland; Arne K Sandvik
Journal:  Scand J Gastroenterol       Date:  2010-04       Impact factor: 2.423

Review 6.  Strategies for Effective Discontinuation of Proton Pump Inhibitors.

Authors:  Judith Kim; John W Blackett; Daniela Jodorkovsky
Journal:  Curr Gastroenterol Rep       Date:  2018-05-16

7.  Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis.

Authors:  Willy Gomm; Klaus von Holt; Friederike Thomé; Karl Broich; Wolfgang Maier; Anne Fink; Gabriele Doblhammer; Britta Haenisch
Journal:  JAMA Neurol       Date:  2016-04       Impact factor: 18.302

8.  Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study.

Authors:  Mette Charlot; Erik L Grove; Peter Riis Hansen; Jonas B Olesen; Ole Ahlehoff; Christian Selmer; Jesper Lindhardsen; Jan Kyst Madsen; Lars Køber; Christian Torp-Pedersen; Gunnar H Gislason
Journal:  BMJ       Date:  2011-05-11

9.  Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis.

Authors:  Rhanderson N Cardoso; Alexandre M Benjo; James J DiNicolantonio; Daniel C Garcia; Francisco Y B Macedo; Georges El-Hayek; Girish N Nadkarni; Sebastiano Gili; Mario Iannaccone; Ioannis Konstantinidis; John P Reilly
Journal:  Open Heart       Date:  2015-06-30

10.  Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans.

Authors:  Yan Xie; Benjamin Bowe; Tingting Li; Hong Xian; Yan Yan; Ziyad Al-Aly
Journal:  BMJ Open       Date:  2017-07-04       Impact factor: 2.692

View more
  4 in total

1.  Pre-existing Proton Pump Inhibitor Treatment and Short-Term Prognosis of Acute Myocardial Infarction Patients.

Authors:  Juntao Xie; Qingui Chen; Dejian He
Journal:  Front Cardiovasc Med       Date:  2022-07-04

2.  Proton pump inhibitor usage is associated with higher all-cause mortality and CV events in peritoneal dialysis patients.

Authors:  Yingsi Zeng; Lingling Liu; Liya Zhu; Xiaojiang Zhan; Fenfen Peng; Xiaoran Feng; Qian Zhou; Yujing Zhang; Zebin Wang; Jianbo Liang; Jiao Li; Yueqiang Wen
Journal:  Ren Fail       Date:  2022-12       Impact factor: 2.606

3.  Updated Insights on Cardiac and Vascular Risks of Proton Pump Inhibitors: A Real-World Pharmacovigilance Study.

Authors:  Yinghong Zhai; Xiaofei Ye; Fangyuan Hu; Jinfang Xu; Xiaojing Guo; Zhen Lin; Xiang Zhou; Zhijian Guo; Yang Cao; Jia He
Journal:  Front Cardiovasc Med       Date:  2022-02-25

Review 4.  Rebuilding trust in proton pump inhibitor therapy.

Authors:  Alla Turshudzhyan; Sonia Samuel; Angela Tawfik; Micheal Tadros
Journal:  World J Gastroenterol       Date:  2022-06-28       Impact factor: 5.374

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.